KCNQ1OT1 and colorectal carcinoma: Together, studies suggest that higher levels of KCNQ1OT1 in CRC patients could reduce the effectiveness of some chemotherapeutic regimens and may be useful as a predictive biomarker of drug response, a prognostic indicator, and an immune therapy target.